In summary, in the VERTIS CV study, the use of the SGLT2 inhibitor ertugliflozin resulted in a decreased occurrence of OSA in individuals with type 2 diabetes. This evidence concerns the gene SLC5A2 and obstructive sleep apnea syndrome.